Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

BACKGROUND: A subset of patients treated with initial anti-vascular endothelial growth factor (VEGF) therapy exhibit progressive disease (PD) as the best response per RECIST criteria. METHODS: Data from patients with metastatic renal cell carcinoma (mRCC) treated with anti-VEGF therapy were collecte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Heng, D. Y., MacKenzie, M. J., Vaishampayan, U. N., Bjarnason, G. A., Knox, J. J., Tan, M. H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B. I., Choueiri, T. K.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858023/
https://ncbi.nlm.nih.gov/pubmed/22056973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr533
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars